Following-up of a four-dose daclizumab induction therapy without calcineurin inhibitors in a liver transplantation recipient with severe renal dysfunction: a case report.
There is debate on the dose schedule and pharmacokinetics of daclizumab in liver transplant recipients. A four-dose course of daclizumab was administered to a patient with severe renal dysfunction. Calcineurin inhibitor therapy initiation was delayed to 86 days posttransplantation. The patient is well as 480 days after transplantation. No rejection was observed. The result suggested the efficacy of our dose schedule, but it will be necessary to confirm it with further pharmacokinetic studies and more cases.